An open-label, non-controlled, multicenter, multinational Study to evaluate the Efficacy and Safety of Zemaira administration in Chronic Augmentation and Maintenance Therapy in Subjects with Emphysema due to Alpha1-Proteinase Inhibitor Deficiency who completed Clinical Study CE1226_4001

Trial Profile

An open-label, non-controlled, multicenter, multinational Study to evaluate the Efficacy and Safety of Zemaira administration in Chronic Augmentation and Maintenance Therapy in Subjects with Emphysema due to Alpha1-Proteinase Inhibitor Deficiency who completed Clinical Study CE1226_4001

Completed
Phase of Trial: Phase IV

Latest Information Update: 24 May 2017

At a glance

  • Drugs Alpha 1-antitrypsin (Primary)
  • Indications Emphysema
  • Focus Therapeutic Use
  • Acronyms RAPID Extension trial
  • Sponsors CSL Behring
  • Most Recent Events

    • 24 May 2017 Results Post-Hoc Analysis of the RAPID/RAPID Extension Trialpresented at the 113th International Conference of the American Thoracic Society
    • 02 Dec 2016 Data from this trial published in the Lancet Respiratory Medicine, as per a CSL Behring media release.
    • 12 Mar 2016 Results of dose-exposure and exposure response analysis from RAPID and RAPID extension trials, presented at the 117th Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top